on INVENTIVA (EPA:IVA)
Inventiva announces the issuance of royalty certificates for an amount of 20.1 million euros
Biopharmaceutical company Inventiva announced the issuance of royalty certificates worth €20.1 million. These certificates were subscribed by Samsara BioCapital and existing shareholders such as BVF Partners, NEA, Sofinnova and Yiheng.
These royalty certificates will entitle their holders to 3% of future net sales of lanifibranor in the United States, European Union and United Kingdom over a period of 14 years. Lanifibranor is currently undergoing a Phase III trial for the treatment of non-alcoholic steatohepatitis.
Frédéric Cren, CEO of Inventiva, said this agreement extends Inventiva's cash position until September 2024. The company is also considering other strategic and financial options to continue the development of lanifibranor.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INVENTIVA news